Results 11 to 20 of about 411,749 (186)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Diabetes, Metabolic Syndrome and Obesity, 2010
Jean-Pierre Le FlochDepartment of Diabetology, Medical Clinic, Villecresnes, FranceAbstract: Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action.
Jean-Pierre Le Floch
doaj   +4 more sources

Insulin detemir in the treatment of type 1 and type 2 diabetes [PDF]

Vascular Health and Risk Management, 2006
Jean-Christophe Philips, André ScheenDivision of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart-Tilman, University of Liège, Liège, Belgium Abstract: Insulin detemir is a soluble long-acting human ...
Jean-Christophe Philips, André Scheen   +1 more
doaj   +2 more sources

Detemir as a once-daily basal insulin in type 2 diabetes

Clinical Pharmacology: Advances and Applications, 2011
Scott E NelsonCleveland Family Medicine, Cleveland, Mississippi, USABackground: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus ...
Nelson SE
doaj   +1 more source

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

Patient Preference and Adherence, 2008
Athena Philis-TsimikasScripps Whittier Diabetes Institute, La Jolla, CA, USAAbstract: The progressive nature of type 2 diabetes poses challenges in the clinic: treatment must be continually reviewed and adjusted in response to the patient’s ...
Athena Philis-Tsimikas
doaj   +1 more source

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

Diabetes, Metabolic Syndrome and Obesity, 2011
Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T   +8 more
doaj   +1 more source

Insulin detemir for the treatment of obese patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2012
Priscilla A Hollander1,21Baylor Endocrine Center, 2Baylor Medical Center, Dallas, Texas, USAAbstract: The risk for developing type 2 diabetes (T2DM) is greater among obese individuals. Following onset of the disease, patients with T2DM become more likely
Hollander PA
doaj   +1 more source

Insulin detemir and basal insulin therapy.

Endocrinology and Metabolism Clinics of North America, 2007
With the introduction of insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]), a long-acting basal insulin analog, it is an opportune moment to reevaluate the use of basal insulin therapy and consider current treatment strategies, including ...
Russell-Jones, DL
core   +4 more sources

The role of insulin detemir in overweight type 2 diabetes management

Vascular Health and Risk Management, 2009
Yared N Demssie1, Naveed Younis2, Handrean Soran31Department of Diabetes and Endocrinology, Salford Royal Foundation NHS Trust, Salford, UK; 2Department of Medicine, University Hospital South Manchester Foundation NHS Trust, Wythenshawe, Manchester, UK ...
Yared N Demssie, Naveed Younis, Handrean Soran   +2 more
doaj   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus. [PDF]

Diabetes Obes Metab
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Bolli GB, Home PD, Lepore M, Riddle MC, Porcellati F, Fanelli CG, Lucidi P, Yki-Järvinen H, Becker RH, Owens DR.   +9 more
europepmc   +2 more sources

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes - A randomized clinical trial [PDF]

, 2004
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations.
Bartley, Paul, Russell-Jones, David, Lang, Hanne, Landin-Olsson, M., Lang, H., Hanaire-Broutin, Helene, Draeger, Eberhard, Hanaire-Broutin, H., Abrams, Pascale, Landin-Olsson, Mona,, Russell-Jones, D., Bartley, Paul Anthony, Draeger, E., Hylleberg, Birgitte, Bartley, P., Hylleberg, B., Heeg, J.E., Home, Philip, Lund University., Home, P., Heeg, Jan-Evert, Landin-Olsson, Mona   +21 more
core   +1 more source